肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2012年
5期
321-323
,共3页
王毓斌%吕永安%邵晋凯%李晓东
王毓斌%呂永安%邵晉凱%李曉東
왕육빈%려영안%소진개%리효동
膀胱肿瘤%激光%经尿道膀胱肿瘤电切术
膀胱腫瘤%激光%經尿道膀胱腫瘤電切術
방광종류%격광%경뇨도방광종류전절술
Urinary bladder neoplasms%Laser%Transurethral resection of bladder tumor
目的 比较2μm激光膀胱肿瘤切除术与经尿道膀胱肿瘤电切术(TURBT)治疗非肌层浸润性膀胱肿瘤的安全性与疗效,评价2μm激光治疗非肌层浸润性膀胱肿瘤的临床应用价值.方法 62例非肌层浸润性膀胱肿瘤患者按照随机数字表法分为两组,32例行2μm激光膀胱肿瘤切除术(2μm激光组),30例行TURBT(TURBT组),记录手术时间、出血情况、相关并发症、导尿管留置时间、膀胱持续冲洗时间、术后住院天数及术后复发情况等.术后定期行吡柔比星膀胱灌注化疗.结果 两组手术均成功,所有患者均未输血,2μm激光组手术时间(32.5±10.5) min,与TURBT组的(31.3±9.8) min比较差异无统计学意义(t=0.364,P=0.674).2μm激光组未出现闭孔神经反射,TURBT组为3例.2μm激光组和TURBT组术后平均膀胱冲洗时间分别为(6.2±2.6)h和(23.8±6.5)h(t=8.294,P=0.006);术后平均留置尿管时间分别为(4.2±1.5)d和(5.2±1.8)d (t=1.468,P=0.103)；术后平均住院时间分别为(5.3±1.5)d和(5.8±2.8)d(t=0.627,P=0.531).术后随访6～ 18个月,2μm激光组3例复发,复发率9.4％,TURBT组3例复发,复发率10.0％,两组复发率差异无统计学意义(x2=0.481,P=0.562).结论 2μm激光治疗非肌层浸润性膀胱肿瘤疗效确切,与TURBT相似,且具有并发症少、恢复快等优点.
目的 比較2μm激光膀胱腫瘤切除術與經尿道膀胱腫瘤電切術(TURBT)治療非肌層浸潤性膀胱腫瘤的安全性與療效,評價2μm激光治療非肌層浸潤性膀胱腫瘤的臨床應用價值.方法 62例非肌層浸潤性膀胱腫瘤患者按照隨機數字錶法分為兩組,32例行2μm激光膀胱腫瘤切除術(2μm激光組),30例行TURBT(TURBT組),記錄手術時間、齣血情況、相關併髮癥、導尿管留置時間、膀胱持續遲洗時間、術後住院天數及術後複髮情況等.術後定期行吡柔比星膀胱灌註化療.結果 兩組手術均成功,所有患者均未輸血,2μm激光組手術時間(32.5±10.5) min,與TURBT組的(31.3±9.8) min比較差異無統計學意義(t=0.364,P=0.674).2μm激光組未齣現閉孔神經反射,TURBT組為3例.2μm激光組和TURBT組術後平均膀胱遲洗時間分彆為(6.2±2.6)h和(23.8±6.5)h(t=8.294,P=0.006);術後平均留置尿管時間分彆為(4.2±1.5)d和(5.2±1.8)d (t=1.468,P=0.103)；術後平均住院時間分彆為(5.3±1.5)d和(5.8±2.8)d(t=0.627,P=0.531).術後隨訪6～ 18箇月,2μm激光組3例複髮,複髮率9.4％,TURBT組3例複髮,複髮率10.0％,兩組複髮率差異無統計學意義(x2=0.481,P=0.562).結論 2μm激光治療非肌層浸潤性膀胱腫瘤療效確切,與TURBT相似,且具有併髮癥少、恢複快等優點.
목적 비교2μm격광방광종류절제술여경뇨도방광종류전절술(TURBT)치료비기층침윤성방광종류적안전성여료효,평개2μm격광치료비기층침윤성방광종류적림상응용개치.방법 62례비기층침윤성방광종류환자안조수궤수자표법분위량조,32례행2μm격광방광종류절제술(2μm격광조),30례행TURBT(TURBT조),기록수술시간、출혈정황、상관병발증、도뇨관류치시간、방광지속충세시간、술후주원천수급술후복발정황등.술후정기행필유비성방광관주화료.결과 량조수술균성공,소유환자균미수혈,2μm격광조수술시간(32.5±10.5) min,여TURBT조적(31.3±9.8) min비교차이무통계학의의(t=0.364,P=0.674).2μm격광조미출현폐공신경반사,TURBT조위3례.2μm격광조화TURBT조술후평균방광충세시간분별위(6.2±2.6)h화(23.8±6.5)h(t=8.294,P=0.006);술후평균류치뇨관시간분별위(4.2±1.5)d화(5.2±1.8)d (t=1.468,P=0.103)；술후평균주원시간분별위(5.3±1.5)d화(5.8±2.8)d(t=0.627,P=0.531).술후수방6～ 18개월,2μm격광조3례복발,복발솔9.4％,TURBT조3례복발,복발솔10.0％,량조복발솔차이무통계학의의(x2=0.481,P=0.562).결론 2μm격광치료비기층침윤성방광종류료효학절,여TURBT상사,차구유병발증소、회복쾌등우점.
Objective To compare the safety and efficacy between RevoLix 2 μ m continuous-wave (CW) laser resection of bladder tumor and transurethral resection of bladder tumor (TURBT) in patients with non-muscle-invasive bladder tumor, and to evaluate clinical value of 2 μ m CW laser resection for nonmuscle-invasive bladder tumor. Methods 62 patients with non-muscle-invasive bladder tumor were divided into 2 groups including 2 μ m CW laser resection group (32 cases) and TURBT group (30 cases) according to the random number table.The intravesical instillation of pirarubicin was performed regularly. The operative time,drop in hemoglobin,indwelling catheterization time,and operative complications were analyzed.Results All cases were completed successfully. The mean operative times of 2 μm CW laser resection group and TURBT group were 32.5±10.5 min and 31.3± 9.8 min, respectively, and no statistical difference could be found between both groups (t =0.364,P=0.674).3 cases were found to have obturator nerve reflex in TURBT group,but no obturator nerve reflex was found in 2 μn CW laser resection group.Bladder irrigation time of 2 μm laser resection group was statistically shorter than that of TURBT group [ (6.2±2.6)h vs (23.8±6.5)h,t =8.294,P=0.006]. There was also no significant difference in postoperative catheterization time between both groups [(4.2±1.5)d vs (5.2±1.8)d,t=1.468,P=0.103 ]. Postoperative hospitalization time of the two groups was not shown significant difference [ (5.3± 1.5) d vs (5.8±2.8) d,t =0.627,P =0.531 ].All cases were followed up for 6～18 months,and there were no significant difference in the recurrence rate between both groups (x2=0.481,P =0.562). Conclusion 2 μm CW laser resection is a novel excellent treatment for non-muscle-invasive bladder tumor and has the similar effect as TURBT with the advantage of significantly less blood loss and rapid recovery after surgery.
